Keywords: Merck KGaA, Cilengitide, Ph III, Glioblastoma

Merck KGaA's glioblastoma candidate cilengitide fails in Ph III study

Article | 25 February 2013

Print This

German drug major Merck KGaA (MRK: DE) revealed this morning that the Phase III CENTRIC trial of the investigational integrin ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in